Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition. People with AATD do not produce enough of a protective protein, which can cause lung damage known as emphysema. This makes breathing difficult and can worsen over time. This Phase 2 trial is evaluating an experimental medicine called SAR447537 (also known as INBRX-101). The treatment aims to replace the missing protein to help protect the lungs. In this study, researchers want to see how safe the drug is when taken over a longer period and how well it works. The study is 'open-label', meaning every participant receives the real medicine rather than a dummy drug (placebo). It is open to non-smoking adults aged 18 to 80 who have emphysema caused by AATD. Participants will have regular clinic visits for health checks, blood tests, and breathing tests to monitor their response.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
Sanofi
Einschreibeziel
185
Starten
20. Juni 2024
Geschätzte Fertigstellung
30 Sep 2028

Worum geht es in dieser Studie?

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition passed down through families. Normally, the liver produces a protein that protects the lungs from irritation and infection. Without enough of this protein, natural enzymes in the body can slowly break down delicate lung tissue. This causes emphysema, a condition where the tiny air sacs in the lungs become damaged, leading to chronic shortness of breath, coughing, and tiredness.

Currently, there are limited treatment options available on the NHS to replace this missing protein. This trial is investigating a new, lab-developed protein therapy called SAR447537 (INBRX-101). It is designed to act like the natural protective protein, staying in the body longer to help shield lung tissue from ongoing damage.

This is a Phase 2 'open-label extension' study. In clinical trials, 'open-label' means that both you and the study doctors know you are receiving the active medicine, so nobody receives an inactive placebo. The term 'extension' means this study follows patients over an extended time to see how well the medicine works in the long run and to check for any unexpected side effects.

Taking part helps researchers discover whether this new medicine could become a safe, regular treatment for people with AATD emphysema in the future, potentially helping people stay active and preserve their lung health.

Wichtige Erkenntnisse

  • Tests a new medicine (SAR447537) designed to protect lungs in adults with AATD emphysema.
  • Open to non-smoking adults aged 18 to 80 with confirmed AATD and emphysema.
  • This is an open-label study, so all participants receive the active medicine rather than a placebo.
  • The treatment is given as an intravenous drip during regular hospital visits.
  • Participation is entirely voluntary, and you can leave the study at any time.

Wer könnte berechtigt sein?

This study is open to men and women aged between 18 and 80 who have a confirmed diagnosis of alpha-1 antitrypsin deficiency (AATD) and show signs of emphysema caused by the condition. To join, your lung function needs to be at a moderate level (your breathing test score must show at least 30% of what is expected for your age and height), and you must be a non-smoker.

You will not be able to join if you have recently received certain other protein treatments (augmentation therapy) in the last five weeks, or if you have had other biologic treatments in the past 30 days. People who are on an active waiting list for a lung or liver transplant cannot take part.

Additionally, the study is not suitable for people with poorly controlled diabetes, active cancer, severe liver disease, or serious heart problems. If you have recently had a chest infection or a sudden flare-up of your breathing symptoms within the past four weeks, you would need to wait until your health is stable before being considered.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged between 18 and 80 years old.
  2. I have been diagnosed with Alpha-1 Antitrypsin Deficiency (AATD) and emphysema.
  3. I am currently a non-smoker.
  4. I have not had protein replacement (augmentation) therapy in the past 5 weeks.
  5. I have not had a chest infection or severe breathing flare-up in the last 4 weeks.
  6. I am not currently on a waiting list for a lung or liver transplant.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, you will attend an initial screening visit to check your overall health and confirm that the trial is safe for you. This includes breathing tests (spirometry), blood tests, heart checks (ECGs), and physical examinations.

During the study, you will receive SAR447537 as an intravenous infusion (a slow drip into a vein in your arm) at regular hospital visits. The study team will closely monitor you during and after each infusion for any reactions. You will also have scheduled follow-up visits to check your lung function, assess your symptoms, and take routine blood samples. Because this is a long-term study, taking part involves a sustained commitment over several months to years, with regular contact with the specialist research team.

Potenzielle Risiken und Vorteile

A potential benefit of joining is receiving a new treatment designed to protect your lungs, alongside frequent, high-quality care and monitoring from specialist lung doctors. However, there is no guarantee the medicine will improve your breathing. As with any experimental drug, there are risks of side effects, including allergic reactions or irritation at the infusion site, as well as risks that are not yet known. Attending regular hospital appointments also requires time and travel. Taking part is completely your choice, and you can withdraw from the study at any time without giving a reason and without it affecting your standard NHS care.

Standorte (40)

  • UAB Lung Health Center- Site Number : 105
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten
  • St Joseph's Hospital and Medical Center- Site Number : 126
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • David Geffen School of Medicine at UCLA- Site Number : 124
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • University of California Davis Medical Center- Site Number : 110
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • National Jewish Medical and Research Center- Site Number : 123
    Verifizierte Postleitzahl
    Denver, Vereinigte Staaten
  • Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119
    Verifizierte Postleitzahl
    Danbury, United States
  • University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101
    Verifizierte Postleitzahl
    Gainesville, Vereinigte Staaten
  • Indiana University- Site Number : 127
    Verifizierte Postleitzahl
    Indianapolis, Vereinigte Staaten
  • Brigham and Women's Hospital -75 Francis Street- Site Number : 131
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten
  • University of Minnesota-420 Delaware Str SE- Site Number : 125
    Verifizierte Postleitzahl
    Minneapolis, Vereinigte Staaten
  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111
    Verifizierte Postleitzahl
    Hannibal, United States
  • Columbia University Irving Medical Center- Site Number : 104
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten

Häufige Fragen

What does 'open-label' mean?

It means there is no placebo (dummy medicine) used in this trial. Both you and the study doctors will know that you are receiving the real study treatment.

Do I have to pay to take part?

No. The study medicine and all study-related health tests are provided free of charge. Most trials also reimburse reasonable travel and parking costs.

Will this medicine cure my condition?

No. AATD is a lifelong genetic condition. The aim of this treatment is to replace missing protein and help slow or prevent further damage to your lungs, rather than cure the root cause.

Can I still see my usual GP and chest doctor?

Yes. The clinical trial team will work alongside your normal healthcare providers and keep them informed about your care throughout the study.

What happens if I change my mind after starting?

You are free to leave the trial at any point. Your decision will not change the standard of medical care you receive from the NHS now or in the future.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.